Down goes Mylan.

Pounded. 

Mylan NV (MYL) said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of  GlaxoSmithKline plc's (GSK) asthma drug Advair.

The FDA will issue a complete response letter, which indicates that an application is not yet ready for approval, on June 27.

Shares of Mylan fell 4.3% to $39.90 in after-hours trading. GlaxoSmithKline's American Depository Receipts were up 2.5% to $42.15.

"Because our Abbreviated New Drug Application has received a priority designation, our approval could be received prior to the standard 90-day time period following the date of our response to the Complete Response Letter," Mylan said.

More from Markets

Fossil Shares Rise After Company Announces Plan to Sell Tech to Google

Fossil Shares Rise After Company Announces Plan to Sell Tech to Google

Netflix Shares Fall After Company Reports Mixed Earnings Results

Netflix Shares Fall After Company Reports Mixed Earnings Results

3 Things to Know at the Market Close: Bank Earnings, GDP Report and Jim Cramer

3 Things to Know at the Market Close: Bank Earnings, GDP Report and Jim Cramer

Morgan Stanley Sinks as Profit Misses Estimates Amid Trading Slump

Morgan Stanley Sinks as Profit Misses Estimates Amid Trading Slump

IBM to Run Vodafone's Cloud Business, Offer Solutions to Its European Customers

IBM to Run Vodafone's Cloud Business, Offer Solutions to Its European Customers